Esperion Therapeutics Inc (ESPR)
2.08
+0.02
(+0.97%)
USD |
NASDAQ |
May 03, 16:00
2.08
0.00 (0.00%)
After-Hours: 20:00
Esperion Therapeutics Gross Profit Margin (Quarterly): 64.49% for Dec. 31, 2023
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 64.49% |
| September 30, 2023 | 60.62% |
| June 30, 2023 | 73.68% |
| March 31, 2023 | 52.11% |
| December 31, 2022 | 77.89% |
| September 30, 2022 | 65.72% |
| June 30, 2022 | 51.30% |
| March 31, 2022 | 62.17% |
| Date | Value |
|---|---|
| December 31, 2021 | 67.05% |
| September 30, 2021 | 61.43% |
| June 30, 2021 | 95.57% |
| March 31, 2021 | 77.64% |
| December 31, 2020 | 82.49% |
| September 30, 2020 | 92.83% |
| June 30, 2020 | 99.81% |
| March 31, 2020 | 98.32% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
51.30%
Minimum
Jun 2022
99.81%
Maximum
Jun 2020
73.94%
Average
70.37%
Median
Gross Profit Margin (Quarterly) Benchmarks
| United Therapeutics Corp | 89.24% |
| Dynavax Technologies Corp | 84.37% |
| Heron Therapeutics Inc | 71.12% |
| Aldeyra Therapeutics Inc | -- |
| Deciphera Pharmaceuticals Inc | 96.30% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -90.08% |
| Profit Margin (Quarterly) | -174.7% |
| Operating Margin (Quarterly) | -131.4% |
| Return on Net Operating Assets | -224.4% |